These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

665 related articles for article (PubMed ID: 22249003)

  • 1. Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys.
    Yamaoka M; Hara T; Hitaka T; Kaku T; Takeuchi T; Takahashi J; Asahi S; Miki H; Tasaka A; Kusaka M
    J Steroid Biochem Mol Biol; 2012 Apr; 129(3-5):115-28. PubMed ID: 22249003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of a novel 17,20-lyase inhibitor, orteronel (TAK-700), on androgen synthesis in male rats.
    Hara T; Kouno J; Kaku T; Takeuchi T; Kusaka M; Tasaka A; Yamaoka M
    J Steroid Biochem Mol Biol; 2013 Mar; 134():80-91. PubMed ID: 23146910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of an investigational CYP17A1 inhibitor, orteronel (TAK-700), on estrogen- and corticoid-synthesis pathways in hypophysectomized female rats and on the serum estradiol levels in female cynomolgus monkeys.
    Yamaoka M; Hara T; Araki H; Kaku T; Hitaka T; Tasaka A; Kusaka M
    J Steroid Biochem Mol Biol; 2013 Nov; 138():298-306. PubMed ID: 23856460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The hunt for a selective 17,20 lyase inhibitor; learning lessons from nature.
    Bird IM; Abbott DH
    J Steroid Biochem Mol Biol; 2016 Oct; 163():136-46. PubMed ID: 27154414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the adrenal gland in castration-resistant prostate cancer: a case for orteronel, a selective CYP-17 17,20-lyase inhibitor.
    Zhu H; Garcia JA
    Curr Oncol Rep; 2013 Apr; 15(2):105-12. PubMed ID: 23371447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel nonsteroidal inhibitor of cytochrome P450(17alpha) (17alpha-hydroxylase/C17-20 lyase), YM116, decreased prostatic weights by reducing serum concentrations of testosterone and adrenal androgens in rats.
    Ideyama Y; Kudoh M; Tanimoto K; Susaki Y; Nanya T; Nakahara T; Ishikawa H; Yoden T; Okada M; Fujikura T; Akaza H; Shikama H
    Prostate; 1998 Sep; 37(1):10-8. PubMed ID: 9721064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specificity of anti-prostate cancer CYP17A1 inhibitors on androgen biosynthesis.
    Udhane SS; Dick B; Hu Q; Hartmann RW; Pandey AV
    Biochem Biophys Res Commun; 2016 Sep; 477(4):1005-1010. PubMed ID: 27395338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting of CYP17A1 Lyase by VT-464 Inhibits Adrenal and Intratumoral Androgen Biosynthesis and Tumor Growth of Castration Resistant Prostate Cancer.
    Maity SN; Titus MA; Gyftaki R; Wu G; Lu JF; Ramachandran S; Li-Ning-Tapia EM; Logothetis CJ; Araujo JC; Efstathiou E
    Sci Rep; 2016 Oct; 6():35354. PubMed ID: 27748439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I/II trial of orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer.
    Dreicer R; MacLean D; Suri A; Stadler WM; Shevrin D; Hart L; MacVicar GR; Hamid O; Hainsworth J; Gross ME; Shi Y; Webb IJ; Agus DB
    Clin Cancer Res; 2014 Mar; 20(5):1335-44. PubMed ID: 24418642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth inhibition of human prostate cells in vitro by novel inhibitors of androgen synthesis.
    Klus GT; Nakamura J; Li JS; Ling YZ; Son C; Kemppainen JA; Wilson EM; Brodie AM
    Cancer Res; 1996 Nov; 56(21):4956-64. PubMed ID: 8895750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and development of ODM-204: A Novel nonsteroidal compound for the treatment of castration-resistant prostate cancer by blocking the androgen receptor and inhibiting CYP17A1.
    Oksala R; Moilanen A; Riikonen R; Rummakko P; Karjalainen A; Passiniemi M; Wohlfahrt G; Taavitsainen P; Malmström C; Ramela M; Metsänkylä HM; Huhtaniemi R; Kallio PJ; Mustonen MV
    J Steroid Biochem Mol Biol; 2019 Sep; 192():105115. PubMed ID: 29438723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer.
    Petrylak DP; Gandhi JG; Clark WR; Heath E; Lin J; Oh WK; Agus DB; Carthon B; Moran S; Kong N; Suri A; Bargfrede M; Liu G
    Invest New Drugs; 2015 Apr; 33(2):397-408. PubMed ID: 25556680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer.
    Kaku T; Hitaka T; Ojida A; Matsunaga N; Adachi M; Tanaka T; Hara T; Yamaoka M; Kusaka M; Okuda T; Asahi S; Furuya S; Tasaka A
    Bioorg Med Chem; 2011 Nov; 19(21):6383-99. PubMed ID: 21978946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of the potential of polyphenols as a CYP17 inhibitor free of adverse corticosteroid elevation.
    Lin CJ; Cheng LC; Lin TC; Wang CJ; Li LA
    Biochem Pharmacol; 2014 Aug; 90(3):288-96. PubMed ID: 24875446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Orteronel for the treatment of prostate cancer.
    Van Hook K; Huang T; Alumkal JJ
    Future Oncol; 2014 Apr; 10(5):803-11. PubMed ID: 24799061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P450-dependent enzymes as targets for prostate cancer therapy.
    De Coster R; Wouters W; Bruynseels J
    J Steroid Biochem Mol Biol; 1996 Jan; 56(1-6 Spec No):133-43. PubMed ID: 8603034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural and Functional Evaluation of Clinically Relevant Inhibitors of Steroidogenic Cytochrome P450 17A1.
    Petrunak EM; Rogers SA; Aubé J; Scott EE
    Drug Metab Dispos; 2017 Jun; 45(6):635-645. PubMed ID: 28373265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical assessment of Orteronel(®), a CYP17A1 enzyme inhibitor in rats.
    Zainuddin M; Vinod AB; Gurav SD; Police A; Kumar A; Mithra C; Dewang P; Kethiri RR; Mullangi R
    Eur J Drug Metab Pharmacokinet; 2016 Feb; 41(1):1-7. PubMed ID: 25297456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. YM116, 2-(1H-imidazol-4-ylmethyl)-9H-carbazole, decreases adrenal androgen synthesis by inhibiting C17-20 lyase activity in NCI-H295 human adrenocortical carcinoma cells.
    Ideyama Y; Kudoh M; Tanimoto K; Susaki Y; Nanya T; Nakahara T; Ishikawa H; Fujikura T; Akaza H; Shikama H
    Jpn J Pharmacol; 1999 Feb; 79(2):213-20. PubMed ID: 10202857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors.
    Cai C; Chen S; Ng P; Bubley GJ; Nelson PS; Mostaghel EA; Marck B; Matsumoto AM; Simon NI; Wang H; Chen S; Balk SP
    Cancer Res; 2011 Oct; 71(20):6503-13. PubMed ID: 21868758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.